<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyEventTranscriptSummaryOutput xmlns:ns2="local" id="4971123"><Name>ONCOLYTICS BIOTECH INC to discuss in more depth the Company's Phase III study in head and neck cancers - Conference Call</Name><Company>Oncolytics Biotech Inc</Company><Drugs><Drug>paclitaxel</Drug><Drug>bevacizumab</Drug><Drug>the-105</Drug><Drug>antiviral (respiratory virus infections), ARMS Pharmaceuticals</Drug><Drug>pelareorep (cancer), Oncolytics</Drug><Drug>carboplatin</Drug><Drug>cetuximab</Drug></Drugs></ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyEventTranscriptSummaryOutput>